Cerecor to Present at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016

BALTIMORE–(BUSINESS WIRE)– Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company
developing treatments to make a difference in the lives of patients with
neurological and psychiatric disorders, today announced it will be
featured as a presenting company at the 18^th Annual Rodman &
Renshaw Global Investment Conference, sponsored by H.C. Wainwright &
Co., LLC. The conference is being held on September 11-13, 2016, at
Lotte New York Palace Hotel in New York City.

Dr. Uli Hacksell, President and Chief Executive Officer of Cerecor, will
provide an overview of the Company’s business during the live
presentation and will be available to participate in one-on-one meetings
with investors who are registered to attend the conference.

If you are an institutional investor, and would like to attend the
Company’s presentation, please click on the following link (www.rodmanevents.com)
to register for the Rodman & Renshaw conference. Once your registration
is confirmed, you will be prompted to log into the conference website to
request a one-on-one meeting with the Company.

The presentation will be webcast live. To access the webcast, please
visit http://wsw.com/webcast/rrshq26/cerc.
The webcast replay will remain available for 90 days following the live
presentation.

About Cerecor

Cerecor is a biopharmaceutical company with the goal of becoming a
leader in the development of innovative drugs that make a difference in
the lives of patients with neurological and psychiatric disorders. We
are committed to the development of drugs that improve lives by applying
our extensive knowledge and experience in central nervous system
disorders. Cerecor is currently pursuing the development of two clinical
Phase 2-stage product candidates: CERC-301 and CERC-501.

CERC-301 is currently in Phase 2 development as an oral, rapidly acting
adjunctive treatment of patients with severe major depressive disorder,
or MDD, who are failing to achieve an adequate response to their current
antidepressant treatment with a rapid onset of effect. Cerecor received
fast track designation by the United States Food and Drug Administration
in November 2013 for CERC-301 for the treatment of MDD. CERC-301 belongs
to a class of compounds known as antagonists, or inhibitors, of the
N-methyl-D-aspartate, or NMDA, receptor, a receptor subtype of the
glutamate neurotransmitter system that is responsible for controlling
neurological adaptation. We believe CERC-301 will be a first-in-class
medication that will cause a significant reduction in depressive
symptoms in a matter of days, as compared to weeks or months with
conventional therapies, because it specifically blocks the NMDA receptor
subunit 2B, which we believe provides rapid and significant
antidepressant activity without the adverse side effect profile of
non-selective NMDA receptor antagonists.

CERC-501 is currently in Phase 2 development for smoking cessation.
CERC-501 is a potent and selective kappa opioid receptor, or KOR,
antagonist. KORs are believed to play key roles in modulating stress,
mood and addictive behaviors. Ultimately, Cerecor intends to pursue
development of CERC-501 for the treatment of substance use disorders
more broadly (e.g., nicotine, alcohol, and/or cocaine) and as an
adjunctive treatment of MDD. In addition to Cerecor’s Phase 2 trial, two
externally-funded clinical trials are being conducted to evaluate the
use of CERC-501 in treating cocaine addiction and mood disorders. One
study is being conducted under the auspices of the National Institute of
Mental Health and the second study is being funded by a private
foundation.

In addition to our two clinical Phase 2-stage product
candidates, Cerecor has one preclinical stage asset, CERC-406, a brain
penetrant catechol-O-methyltransferase, or COMT, inhibitor with
potential procognitive activity.

For more information about the Company and its products, please visit www.cerecor.com or
contact Mariam E. Morris, Chief Financial Officer, at (443) 304-8002.

Forward-Looking Statements

This press release may include forward-looking statements made pursuant
to the Private Securities Litigation Reform Act of 1995. Forward-looking
statements are statements that are not historical facts. Such
forward-looking statements are subject to significant risks and
uncertainties that are subject to change based on various factors (many
of which are beyond Cerecor’s control), which could cause actual results
to differ from the forward-looking statements. Such statements may
include, without limitation, statements with respect to Cerecor’s plans,
objectives, projections, expectations and intentions and other
statements identified by words such as “projects,” “may,” “will,”
“could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,”
“potential” or similar expressions (including their use in the
negative), or by discussions of future matters such as the development
of product candidates or products, technology enhancements, possible
changes in legislation, and other statements that are not historical.
These statements are based upon the current beliefs and expectations of
Cerecor’s management but are subject to significant risks and
uncertainties, including those detailed in Cerecor’s filings with
the Securities and Exchange Commission. Actual results may differ from
those set forth in the forward-looking statements. Except as required by
applicable law, Cerecor expressly disclaims any obligations or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change in
Cerecor’s expectations with respect thereto or any change in events,
conditions or circumstances on which any statement is based.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160822005114/en/